Effects of rabeprazole on pharmacokinetics of capecitabine.
Not Applicable
Recruiting
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000031182
- Lead Sponsor
- Showa University institute of molecular oncology Showa University School of Medicine, Division of Medical Oncology, Department of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Interstitial pneumonia, pulmonary fibrosis. 2)Ongoing severe infection. 3)Prior treatment with capecitabine. 4)Unstable angina and Myocardial infarction less than 3 months before start of study drug. 5)Patients with severe complications (incontrollable diabetes mellitus or liver cirrhosis). 6)Concurrent cancer that is distinct in primary site. 7)Psychological condition that may interfere with the patient's participation in the study. 8)Pregnant patients. Men and women who want to make baby. 9)Patients with severe drug allergy or those who had severe drug allergy in the past. 10)Concomitant use of Carboxylesterase inducers. 11)Patients who are not appropriate to participate in the study safely.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate Effects of rabeprazole on pharmacokinetics of capecitabine.
- Secondary Outcome Measures
Name Time Method (1) To investigate association with the genetic polymorphism and the pharmacokinetics. (2) To investigate efficacy and toxicity of capecitabine in combination with PPIs.